Update on survival in thalassemia major

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Telfer, Paul ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Deferasirox; Deferiprone; Desferrioxamine; Iron overlaod; Survival; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

AGRANULOCYTOSIS; ANTIVIRAL THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CHELATION THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG SUBSTITUTION; EUROPE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATITIS; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IRON OVERLOAD; LIFE EXPECTANCY; LONG TERM CARE; LOWEST INCOME GROUP; MONOTHERAPY; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; PROPHYLAXIS; PUBLIC HEALTH PROBLEM; SEPSIS; THALASSEMIA MAJOR; TREATMENT OUTCOME; UNITED STATES;

BENZOIC ACIDS; BETA-THALASSEMIA; DEFEROXAMINE; FOLLOW-UP STUDIES; HUMANS; IRON CHELATING AGENTS; PYRIDONES; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 73949117408     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903347336     Document Type: Conference Paper

References (10)

1. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2052.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
3. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91(9):1187-1192.
4. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
5. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
6. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-578.
7. Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Eur J Haematol. 2009;82(5):381-387.
8. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006 ;107(9):3733-3737.
9. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M. Improved survival in thalassaemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica (in press) DOI: 10.3324/ haematol.2009.009118.
10. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2& cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):42.